Tilman S.A.   Report issue

For profit Phase 1
Founded: Baillonville Belgium (1947)
Status: No NME R&D (1947)

Organization Overview

First Clinical Trial
2012
NCT01909037
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Tilman S.A.

Active Ingredients

Drugs in Phase 1 Trials (1)

curcumin (2 trials)

Drugs in Other Trials (5)

boswellia serrata (1 trial)

curcuma longa (1 trial)

quercetin (1 trial)

turmeric (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 6